Royalty Pharma plc is a biopharmaceutical royalty company founded in 1996 that acquires rights to a share of sales from approved and development-stage therapies. The company’s portfolio includes royalties on more than 35 commercial products and 20 development-stage candidates, spanning partners such as Vertex, GSK, Biogen, Roche, Astellas, Pfizer, Johnson & Johnson, AbbVie, Servier, Gilead, Amgen, and Alnylam. Royalty Pharma serves the global life sciences ecosystem by providing non-dilutive capital to academic institutions, research hospitals, not-for-profits, and biotechnology companies. Its investment approach is agnostic to therapeutic area and treatment modality, focusing on therapies that address significant unmet patient needs. The company operates in the United States and international markets, including emerging opportunities in China, and collaborates with global pharmaceutical and biotechnology firms to fund innovation across the drug development value chain.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Asset Management Homepage royaltypharma.com
Sector Financial Services IR page royaltypharma.com/investors
Tags
biopharmaceutical royalties, life sciences funding, drug development financing, non-dilutive capital, therapeutic royalties, clinical trial funding, synthetic royalties, pharmaceutical licensing, biotech investment, portfolio management, Trikafta, Alyftrek, Trelegy, Tysabri, Spinraza, Evrysdi, Xtandi, Tremfya, Imbruvica, Voranigo, Trodelvy, Imdelltra, Amvuttra, pelacarsen, MorphoSys Development Funding Bonds
Press page —

Metrics

Valuation  
Market cap $ 38.017B
Market cap (USD) $ 38.017B
P/E 44.90
PEG 0.28
P/BV 3.88
P/S 14.53
P/OCF 12.84
P/FCF 15.27
Dividend yield —
Turnover / mcap —
Returns  
ROE 7.7%
ROI 4.1%
ROIC 6.3%
Profit margin 32.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 162.1%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 87.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 56
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 2.378B 2.264B 2.355B 2.237B 2.289B 2.122B 1.814B 0
Net profit 770.947M 858.983M 1.135B 42.832M 619.728M 975.04M 2.349B -18.396M
Free cash flow 2.49B 2.769B 2.988B 2.144B 2.018B — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 38.64 25.51 28.09 39.52 39.85 50.05 — 0.67
Price performance 12m 0.51 -0.09 -0.29 -0.01 -0.2 — — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — 282M 0.00 0.00 998M 0.00 998M 380M
Borrowings, non-current (USD) — — 5.96B 5.82B 7.1B 6.12B 6.14B 6.61B 8.57B
Lease liabilities (USD) — — — — — — — — 19.3M
Cash and deposits (USD) 1.38B 1.92B 284M 1.01B 1.54B 1.71B 477M 929M 619M
Intangible assets (USD) — — 51.7M 28.7M 5.67M 0.00 — — —
Net debt (borrowings + leases - cash) (USD) — — 5.95B 4.81B 5.56B 5.41B 5.66B 6.68B 8.35B
Cash flow detail
Operating cash flow (USD) — 1.62B 1.67B 2.03B 2.02B 2.14B 2.99B 2.77B 2.49B
Change in payables (cash effect) (USD) — 1.35M 6.5M -766,000 -4.59M 2.29M 6.24M -2.29M -13.9M
Share buybacks (cash effect) (USD) — 0.00 -4.27M 0.00 0.00 0.00 -305M -230M -1.23B
Interest paid (cash effect) (USD) — -268M -255M -103M -130M -170M -169M -160M -276M
Share-based compensation (USD) — 0.00 0.00 5.43M 2.44M 2.17M 2.36M 2.34M 290M
Income detail
Research and development expense (USD) — 393M 83M 26.3M 200M 177M 52M 2M 452M
↳ 5y CAGR -33.3% -52.5% +76.6%
Total comprehensive income (USD) — 983M 2.36B 1.04B 1.2B 201M 1.7B 1.33B —
Comprehensive income to owners (USD) — 983M 2.36B 1.03B 598M 25.2M 1.13B 859M —
Reported Feb 24, 2021 Feb 24, 2021 Feb 24, 2021 Feb 24, 2021 Feb 15, 2022 Feb 15, 2024 Feb 15, 2024 Feb 12, 2025 Feb 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Royalty Pharma reports third quarter 2026 results Bull 5 Bear 0 Results

Earnings

4 November 2026

Download PDF

  • Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9%
  • Net cash provided by operating activities of $686 million
  • Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million

NEW YORK, NY, November 4, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.

“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra. Lastly, we remain excited by the potential for R&D co-funding with global biopharma – where we have announced $1 billion of transactions so far this year – which represents an important new opportunity for our business. Looking ahead, with a robust deal pipeline and strong fundamental tailwinds supporting our business, we remain well positioned as a premier capital allocator in life sciences to deliver consistent, compounding growth.”

Strong growth in Royalty Receipts in the third quarter of 2026

  • Royalty Receipts grew 9% to $883 million, driven by Tremfya, Voranigo, Evrysdi and Imdelltra.
  • Portfolio Receipts increased by 9% to $890 million, reflecting higher milestones and other contractual receipts.

Continued healthy transaction activity

  • Acquired a royalty on Arcutis Biotherapeutics’ Zoryve for $100 million and on Takeda’s Mimrylo for $100 million.
  • Announced value of transactions of $1.9 billion and Capital Deployment of $1.6 billion as of November 3, 2026.

Positive regulatory and clinical updates across royalty portfolio

  • FDA approvals for Revolution Medicines’ Rasonque (daraxonrasib) for metastatic pancreatic cancer, Teva’s Weltruza (olanzapine LAI) for schizophrenia and Jazz and BeOne’s Ziihera for HER2+ metastatic gastric cancer.
  • Positive Phase 3 results for Amgen’s Imdelltra as a first-line maintenance therapy for small cell lung cancer and Pharvaris’ deucrictibant XR for prophylaxis of hereditary angioedema attacks.

Raising financial guidance for full year 2026 (excludes contribution from future transactions)

  • Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,500 million and $3,550 million (previously $3,400 million to $3,500 million), representing expected Royalty Receipts growth of 10% to 11%.
Financial & Liquidity Summary Three Months Ended September 30,
($ and shares in millions; unaudited) 2026 2025 Change
--- --- --- ---
Portfolio Receipts 890 814 9%
--- --- --- ---
Net cash provided by operating activities 686 703 (2)%
Adjusted EBITDA (non-GAAP)* 840 779 8%
Portfolio Cash Flow (non-GAAP)* 673 657 2%
Weighted average Class A ordinary shares outstanding – diluted 557 560 (0)%
*See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.

2026 Financial Outlook

Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows:

Provided November 4, 2026 Previous
Portfolio Receipts $3,500 million to $3,550 million $3,400 million to $3,500 million
Payments for operating and professional costs 5.5% to 6.0% of Portfolio Receipts 5.5% to 6.5% of Portfolio Receipts
Interest paid $350 million to $360 million $350 million to $360 million

Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. The above Portfolio Receipts guidance provided on November 4, 2026 includes expected Royalty Receipts growth of 10% to 11% in 2026.

Royalty Pharma’s full year 2026 guidance reflects an estimated foreign exchange impact of approximately +1% to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2026.

Payments for operating and professional costs in 2026 are expected to decrease as a percentage of Portfolio Receipts, compared to 8.9% in 2025, primarily due to extinguishment of the management fee following the completion of the internalization transaction on May 16, 2025.

Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and the quarterly interest payment schedules for the term loan assumed as part of the internalization transaction and borrowings under our revolving credit facility. In 2026, Royalty Pharma anticipates interest paid to be approximately $350 million to $360 million. Interest paid is anticipated to be a de minimis amount in the fourth quarter of 2026. These projections assume no additional debt financing in 2026. In the third quarter of 2026, Royalty Pharma collected interest of $6 million on its cash and cash equivalents, which partially offset interest paid.

Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.

Portfolio Receipts Highlights

Three Months Ended September 30,
($ in millions; unaudited) 2026 2025 Change
--- --- --- --- --- ---
Products: Marketers: Therapeutic Area:
--- --- --- --- --- ---
Cystic fibrosis franchise Vertex Rare disease 225 222 1%
Trelegy GSK Respiratory 89 96 (6)%
Tremfya Johnson & Johnson Immunology 80 49 61%
Evrysdi Roche Rare disease 71 52 38%
Tysabri Biogen Neuroscience 67 68 (1)%
Voranigo Servier Oncology 55 33 65%
Xtandi Pfizer, Astellas Oncology 51 50 3%
Imbruvica AbbVie, Johnson & Johnson Oncology 31 41 (24)%
Cabometyx/Cometriq Exelixis, Ipsen, Takeda Oncology 24 21 13%
Imdelltra Amgen Oncology 19 — n/a
Trodelvy Gilead Oncology 16 12 30%
Spinraza Biogen Rare disease 14 14 0%
Amvuttra Alnylam Rare disease 10 — n/a
Promacta Novartis Hematology 9 38 (75)%
Other products(5) 121 114 6%
Royalty Receipts 883 811 9%
Milestones and other contractual receipts 7 3 138%
Portfolio Receipts 890 814 9%

Amounts shown in the table may not add due to rounding.

Royalty Receipts was $883 million in the third quarter of 2026, an increase of 9% compared to $811 million in the third quarter of 2025. The increase was primarily driven by Tremfya, Voranigo, Evrysdi and Imdelltra, partially offset by declines from Promacta due to U.S. generic competition and from Imbruvica. Royalty Receipts from Evrysdi included the benefit of the additional royalties acquired in December 2025.

Portfolio Receipts was $890 million in the third quarter of 2026, an increase of 9% compared to $814 million in the third quarter of 2025, primarily driven by the same Royalty Receipts increases noted above, in addition to higher Milestones and other contractual receipts.

Liquidity and Capital Resources

Royalty Pharma’s liquidity and capital resources are summarized below:

As of September 30, 2026, Royalty Pharma had cash and cash equivalents of $514 million and total debt with principal value of $8.8 billion. The reduction in total debt from $9.2 billion as of June 30, 2026 reflects payment of the $380 million term loan in July 2026.

In the third quarter of 2026, Royalty Pharma paid a quarterly dividend of $0.235 per share, equating to $135 million in dividends and distributions.

Royalty Pharma repurchased approximately 1.5 million Class A ordinary shares for $87 million in the third quarter and 3.5 million Class A ordinary shares for $183 million during the first nine months of 2026. The weighted-average number of diluted Class A ordinary shares outstanding for the third quarter of 2026 was 557 million as compared to 560 million for the third quarter of 2025.

Liquidity Summary Three Months Ended September 30,
($ in millions; unaudited) 2026 2025
--- --- ---
Portfolio Receipts 890 814
--- --- ---
Payments for operating and professional costs (50) (34)
Adjusted EBITDA (non-GAAP) 840 779
Interest paid, net (167) (123)
Portfolio Cash Flow (non-GAAP) 673 657

Amounts may not add due to rounding.

  • Adjusted EBITDA (non-GAAP) was $840 million in the third quarter of 2026. Payments for operating and professional costs were 5.6% of Portfolio Receipts. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs.
  • Portfolio Cash Flow (non-GAAP) was $673 million in the third quarter of 2026. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.

Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.

Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $362 million in the third quarter of 2026, consisting primarily of R&D funding for JNJ‑4804 and upfront payments for cliramitug, Zoryve and Mimrylo (see ‘Royalty Transactions’). Capital Deployment was $1.2 billion for the nine months ended September 30, 2026, with the announced value of transactions of $1.9 billion.

The table below details Capital Deployment by category:

Capital Deployment

Three Months Ended September 30, Nine Months Ended September 30,
($ in millions; unaudited) 2026 2025 2026 2025
--- --- --- --- ---
Purchases of available for sale debt securities — — — (75)
--- --- --- --- ---
Acquisitions of financial royalty assets (279) (962) (982) (964)
Development-stage funding payments (70) (51) (193) (402)
Milestone payments (13) — (63) (269)
Contributions from legacy non-controlling interests – R&D — (0) — 0
Capital Deployment (362) (1,013) (1,239) (1,709)

Amounts may not add due to rounding.

Royalty Transactions

As of November 3, 2026, Royalty Pharma has announced new transactions of up to $1.9 billion, which reflects the entire amount of potential capital committed for new transactions, including potential future milestones. In the third quarter of 2026, the following transactions were announced:

  • In September 2026, Royalty Pharma acquired a royalty interest in Zoryve from AstraZeneca for $100 million upfront. Zoryve, marketed by Arcutis Biotherapeutics, is a topical phosphodiesterase type 4 (PDE4) inhibitor approved for atopic dermatitis, seborrheic dermatitis and plaque psoriasis.
  • In August 2026, Royalty Pharma acquired a royalty interest in Mimrylo, formerly known as rusfertide, from Zealand Pharma for $100 million, consisting of $50 million paid upfront and the remaining $50 million payable on the first anniversary of the closing. Marketed by Takeda, Mimrylo is a first-in-class therapy approved for polycythemia vera, a rare and chronic blood disorder.
  • In July 2026, Royalty Pharma acquired a portion of Neurimmune AG’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase 3 first-in-class transthyretin (TTR)-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy, a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart.

The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com.

Key Developments Relating to the Portfolio

The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.

pelabresib In October 2026, Novartis announced that the regulatory submission for pelabresib in myelofibrosis was completed in the European Union, based on the positive Phase 3 MANIFEST-2 study.
Rasonque (daraxonrasib) In October 2026, Revolution Medicines announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion of Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.In October 2026, Royalty Pharma funded the required first $250 million tranche of the up to $750 million senior secured term loans to Revolution Medicines. Additionally, Revolution Medicines elected not to exercise its option for the third royalty funding tranche (which was up to $250 million). Up to an additional $500 million may be available at Revolution Medicines’ option under each of the senior secured term loan and royalty funding agreement, based on the achievement of certain milestones.In August 2026, Revolution Medicines announced that the U.S. Food and Drug Administration (FDA) approved Rasonque for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Niktimvo In October 2026, Syndax Pharmaceuticals (Syndax) announced that the Phase 2 MAXPIRe trial of Niktimvo in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint. Syndax does not plan to move forward with further development in IPF. The results do not affect ongoing trials of Niktimvo in other indications.
Weltruza ****(TEV-’749) In October 2026, Teva Pharmaceuticals (Teva) announced that the FDA approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults.
trontinemab In September 2026, Roche announced that Phase 3 studies of trontinemab in early Alzheimer’s disease have fully enrolled, with data expected in the first half of 2028.
Imdelltra In September 2026, Amgen announced positive results from the Phase 3 DeLLphi-305 study of Imdelltra in combination with Imfinzi as first-line maintenance treatment for extensive-stage small cell lung cancer. The study met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival, and also met secondary endpoints of progression-free survival and objective response rate.
deucrictibant In September 2026, Pharvaris announced positive results from the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release for the prevention of hereditary angioedema (HAE) attacks. The primary endpoint and all secondary efficacy endpoints were met with statistical significance.In July 2026, Pharvaris announced that the FDA accepted its New Drug Application (NDA) for deucrictibant immediate-release for the on-demand treatment of HAE attacks and assigned a Prescription Drug User Fee Act (PDUFA) date of April 23, 2027.
pelacarsen In September 2026, Novartis announced that the Phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events in the overall study population compared to placebo. In the third quarter of 2026, Royalty Pharma recorded a non-cash impairment charge of $150 million related to pelacarsen.
TEV-’408 In September 2026, Teva announced positive topline results from an ongoing Phase 2a study of TEV-’408, an anti-IL-15 antibody, in adults with celiac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8, and was well tolerated, with no safety signals observed to date.In July 2026, Teva announced plans to advance TEV-’408 into a Phase 2b study in patients with non-segmental vitiligo, following positive Phase 1b results.
Mimrylo (rusfertide) In August 2026, Takeda announced that the FDA approved Mimrylo, a hepcidin mimetic peptide, for the treatment of erythrocytosis in adults with polycythemia vera.
Ziihera In August 2026, Jazz Pharmaceuticals announced that the FDA approved Ziihera in combination with chemotherapy, with or without tislelizumab, for the first-line treatment of adults with metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma.
Trodelvy In August 2026, Gilead announced that the European Commission approved Trodelvy in combination with Keytruda as a first-line treatment for PD-L1-positive metastatic triple-negative breast cancer.
ecopipam In August 2026, Teva announced that the FDA accepted its NDA for ecopipam for the treatment of pediatric Tourette syndrome and granted the application Priority Review with a PDUFA date late in the first quarter of 2027.
obexelimab In August 2026, Zenas BioPharma announced that the FDA accepted for review its Biologics License Application for obexelimab for the treatment of immunoglobulin G4-related disease (IgG4-RD) and assigned a PDUFA target action date of May 27, 2027.
Jideytro (zidesamtinib) and neladalkib In July 2026, GSK announced that the FDA approved Jideytro, a ROS proto-oncogene 1 (ROS1)-selective inhibitor, for the treatment of adult patients with metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor.In July 2026, GSK announced that it completed the acquisition of Nuvalent for approximately $10.6 billion, including Jideytro and neladalkib, two highly selective ROS1 and anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.

Financial Results Call

Royalty Pharma will host a conference call and simultaneous webcast to discuss its third quarter of 2026 results today at 8:00 a.m. Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 16 development-stage product candidates.

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

Royalty Pharma declares fourth quarter 2026 dividend Bull 0 Bear 0 Capital return

Earnings

16 October 2026

Download PDF

NEW YORK, NY, October 16, 2026 — The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share.

The dividend will be paid on December 10, 2026, to shareholders of record at the close of business on November 13, 2026.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
[email protected]

Stay up to date

Subscribe to Royalty Pharma news and alerts

Subscribe

Royalty Pharma

110 E 59th Street FL 33
New York, NY 10022
+1 (212) 883-0200

[email protected]

Quick links

© 2026 Royalty Pharma, RP Management LLC. All Rights Reserved.

GDPR Cookie Banner

We value your privacy.

We use essential cookies to operate this website. With your permission, we also use analytics, advertising and social media cookies to understand how our content is used, improve the visitor experience and measure the effectiveness of our communications.

Show details

Accept all Reject all Customise

Change cookie settings

Close GDPR Cookie Settings

  • Privacy Overview
  • Necessary
  • Analytics
  • Marketing
  • Cookie Policy

Powered by  GDPR Cookie Compliance (opens in a new tab)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Necessary

These cookies are required for the website to work and to remember your cookie choices. They cannot be switched off in this tool.

Enabled Disabled

Show details Hide details

Name Provider Purpose Expiration
moove_gdpr_popup Royalty Pharma Remembers your cookie preference and consent category choices for this website. 1 year
__cf_bm Cloudflare Supports bot management and security protection for the website and hosted resources. 30 minutes
_cfuvid Cloudflare Helps apply rate limiting and distinguish visitors who share an IP address. Session
_GRECAPTCHA Google reCAPTCHA Helps protect forms from spam and abuse by supporting reCAPTCHA risk analysis. 179 days

Analytics

These cookies help us understand how people use the website so we can improve content and performance. They are only used if you allow analytics cookies.

Enabled Disabled

Show details Hide details

Name Provider Purpose Expiration
_ga Google Analytics Distinguishes visitors for website analytics and measurement. 399 days
_ga_N7PN9PKQBL Google Analytics Stores and counts page views for the GA4 property used by this website. 399 days
_hjSession_3631739 Hotjar Maintains data for the current Hotjar analytics session. 30 minutes
_hjSessionUser_3631739 Hotjar Persists a site-specific Hotjar user ID so later visits can be attributed to the same analytics user. 365 days
vuid Vimeo Stores a Vimeo-generated ID used to generate analytics information for the video owner. 399 days
__uxq412__id.9a22 Q4 / Q4Web Used by Q4 investor-relations tooling to measure engagement with investor content, including visitor identification for page-view activity. 364 days
__uxq412__ses.9a22 Q4 / Q4Web Used by Q4 investor-relations tooling to measure engagement with investor content during a browsing session. 30 minutes

Marketing

These cookies help us measure campaigns and understand the effectiveness of our marketing. They are only used if you allow marketing cookies.

Enabled Disabled

Cookie Policy

More information about our Cookie Policy

Accept all Save choices Reject all

News

9 October 2026

Download PDF

NEW YORK, NY, October 9, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
[email protected]

Stay up to date

Subscribe to Royalty Pharma news and alerts

Subscribe

Royalty Pharma

110 E 59th Street FL 33
New York, NY 10022
+1 (212) 883-0200

[email protected]

Quick links

© 2026 Royalty Pharma, RP Management LLC. All Rights Reserved.

GDPR Cookie Banner

We value your privacy.

We use essential cookies to operate this website. With your permission, we also use analytics, advertising and social media cookies to understand how our content is used, improve the visitor experience and measure the effectiveness of our communications.

Show details

Accept all Reject all Customise

Change cookie settings

Close GDPR Cookie Settings

  • Privacy Overview
  • Necessary
  • Analytics
  • Marketing
  • Cookie Policy

Powered by  GDPR Cookie Compliance (opens in a new tab)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Necessary

These cookies are required for the website to work and to remember your cookie choices. They cannot be switched off in this tool.

Enabled Disabled

Show details Hide details

Name Provider Purpose Expiration
moove_gdpr_popup Royalty Pharma Remembers your cookie preference and consent category choices for this website. 1 year
__cf_bm Cloudflare Supports bot management and security protection for the website and hosted resources. 30 minutes
_cfuvid Cloudflare Helps apply rate limiting and distinguish visitors who share an IP address. Session
_GRECAPTCHA Google reCAPTCHA Helps protect forms from spam and abuse by supporting reCAPTCHA risk analysis. 179 days

Analytics

These cookies help us understand how people use the website so we can improve content and performance. They are only used if you allow analytics cookies.

Enabled Disabled

Show details Hide details

Name Provider Purpose Expiration
_ga Google Analytics Distinguishes visitors for website analytics and measurement. 399 days
_ga_N7PN9PKQBL Google Analytics Stores and counts page views for the GA4 property used by this website. 399 days
_hjSession_3631739 Hotjar Maintains data for the current Hotjar analytics session. 30 minutes
_hjSessionUser_3631739 Hotjar Persists a site-specific Hotjar user ID so later visits can be attributed to the same analytics user. 365 days
vuid Vimeo Stores a Vimeo-generated ID used to generate analytics information for the video owner. 399 days
__uxq412__id.9a22 Q4 / Q4Web Used by Q4 investor-relations tooling to measure engagement with investor content, including visitor identification for page-view activity. 364 days
__uxq412__ses.9a22 Q4 / Q4Web Used by Q4 investor-relations tooling to measure engagement with investor content during a browsing session. 30 minutes

Marketing

These cookies help us measure campaigns and understand the effectiveness of our marketing. They are only used if you allow marketing cookies.

Enabled Disabled

Cookie Policy

More information about our Cookie Policy

Accept all Save choices Reject all

Prompts

Royalty Pharma plc (ticker RPRX), listed in United States.

ETFs Holding Royalty Pharma plc

ETF Weight in ETF Shares Market value As of
ELCV 3.73% 160,144 $ 9.357M Jul 31, 2026
QMOM 2.59% 143,398 $ 9.85M Nov 18, 2026
SMRI 2.33% 235,952 $ 16.21M Nov 18, 2026
OASC 2.27% 34,669 $ 2.129M Aug 31, 2026
FORH 2.00% 7,024 $ 393.836K Jun 30, 2026
GDOC 1.75% 5,584 $ 342.913K Aug 31, 2026
EHLS 1.47% 11,528 $ 789.956K Nov 17, 2026
CGDG 1.37% 1,197,545 $ 82.062M Nov 16, 2026
VFMV 1.32% 97,512 $ 5.988M Aug 31, 2026
LSEQ 1.30% 3,270 $ 226.644K Nov 13, 2026
INFL 1.24% 326,305 $ 18.296M Jun 30, 2026
UPSD 1.19% 23,863 $ 1.394M Jul 31, 2026
ESLV 0.79% 1,939 $ 113.296K Jul 31, 2026
ESUM 0.72% 22,368 $ 1.307M Jul 31, 2026
FTHI 0.67% 247,519 $ 16.961M Nov 16, 2026
FFF 0.60% 650 $ 37.934K Sep 30, 2026
FTQI 0.52% 72,368 $ 4.959M Nov 16, 2026
JSTC 0.46% 19,943 $ 1.367M Nov 17, 2026
LOPP 0.43% 1,250 $ 70.088K Jun 30, 2026
AVMC 0.31% 24,987 $ 1.712M Nov 16, 2026
VFMO 0.24% 74,775 $ 4.592M Aug 31, 2026
FTLS 0.18% 66,972 $ 0.00 Nov 16, 2026
AVIE 0.16% 383 $ 26.245K Nov 16, 2026
TACU 0.14% 361 $ 24.738K Nov 17, 2026
MSSM 0.13% 15,333 $ 941.6K Aug 31, 2026
SELV 0.13% 5,472 $ 306.815K Jun 30, 2026
IALT 0.08% 95,436 $ 6.54M Nov 16, 2026
XMAG 0.06% 1,882 $ 129.359K Nov 13, 2026
AVSU 0.06% 4,194 $ 287.394K Nov 16, 2026
AVLC 0.06% 12,760 $ 874.379K Nov 16, 2026
FLSP 0.05% 8,703 $ 487.977K Jun 30, 2026
MODL 0.05% 8,840 $ 495.659K Jun 30, 2026
AVUS 0.04% 90,875 $ 6.227M Nov 16, 2026
MSLC 0.02% 14,840 $ 911.324K Aug 31, 2026